‘BhAVI-23’-A spice-herb based dietary infusion possessing in-vitro anti-viral potential

Journal of Ayurveda and Integrative Medicine

Sunil K. Ghosh¹  Satyendra Gautam²  Sachin N. Hajare³  Sudhanshu Saxena³  Sumit Gupta³  Sanjeev Kumar³ 

[1] Food Technology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India;Corresponding author.;Food Technology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India;

关键词: Anti-diabetic;    Anti-viral;    Gas chromatography;    Infusion;    Molecular docking;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Viruses cause many life threatening human diseases. Recently, COVID-19 pandemic has challenged the health care systems worldwide. As a disease preventive approach and to bring relief to the severity of the symptoms, a infusion termed as Bhabha Anti-Viral Infusion-23 (‘BhAVI-23’) was conceptualized and formulated which comprised of 23 selected spices and herbals. Objective: The present study was conducted to assess the in vitro antiviral potential of the formulation, BhaAVI-23. Material and methods: The in-vitro anti-viral potential of BhAVI-23 was assessed through inhibition of HIV1 reverse transcriptase (RT) as well as through a novel P1 (virulent) bacteriphage based screening assay system. Anti-diabetic potential was assessed by non-enzymatic glycosylation of haemoglobin and the bioactive volatile components were detected through headspace gas chromatography followed by molecular docking analysis. Results: The infusion displayed prominent anti-viral activity as evident from significant (57%) inhibition of the HIV1-RT as well as through reduction in the infectivity of P1 (virulent) bacteriophage. The infusion also exerted profound protection (∼64%) to non-enzymatic glycosylation of haemoglobin. Headspace gas chromatography and mass spectrometric analysis confirmed the presence of at least 47 major compounds. Docking analysis indicated possible interaction of α-pinene and eugenol with SARS-CoV spike protein. Conclusion: This ‘BhAVI-23’ infusion displayed prominent in-vitro anti-viral and anti-diabetic potential in different model systems. These attributes have relevance as diabetic patients are more prone to COVID-19 morbidity. ‘BhAVI-23’ opens the avenue for its potential inclusion as a supportive health care system upon due regulatory approval during the current pandemic.

【 授权许可】

Unknown